Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma Inc.

Cue Energy Resources Limited ( ($AU:CUE) ) has issued an announcement. Cue Energy Resources used an MST Financial webinar titled “New Technologies,...

Cue Energy Highlights Portfolio Quality, Growth and Dividends at MST Webinar

An update from Cuentas ( ($CUEN) ) is now available. On January 29, 2026, Cuentas, Inc. entered into an Amended and Restated Warrant Agency Agreeme...

Cuentas Extends Warrant Expiration to Support Strategy

The latest announcement is out from Cue Energy Resources Limited ( ($AU:CUE) ). Cue Energy Resources Limited reported steady quarterly production o...

Cue Energy Holds Production Steady as Long-Term Gas Deals and Drilling Plans Advance

Cue Biopharma ($CUE) announced an update on their ongoing clinical study. Cue Biopharma’s HPV-Linked Head and Neck Cancer Study Reaches Key Milesto...

Cue Biopharma’s CUE-101 Trial Hits Completion: What It Means for Cancer Investors

Chengdu Putian Telecommunications Cable Co., Ltd. Class H ( ($HK:1202) ) has issued an update. Chengdu SIWI Science and Technology Company Limited ...

Market Cap	$54.56M	P/E Ratio	N/A
52W High	$1.54	52W Low	$0.23
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	20.1%	52W Position	7.0%
Overall Score	43	Value Score	60
Quality Score	42	Technical Score	27

EPS Current Est	$-0.41	EPS Next Est	$-0.48
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CUE	$0.32	-4.65%	306.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CUE	$0.32	-4.7%	306.21K
3
4
5
6

CUE

CUE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Cue Biopharma Inc. Data in Excel

Get Cue Biopharma Inc. Data in Excel